# A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

> **NCT06064877** · PHASE3 · RECRUITING · sponsor: **AVEO Pharmaceuticals, Inc.** · enrollment: 410 (estimated)

## Conditions studied

- Metastatic Head-and-neck Squamous-cell Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Ficlatuzumab
- **BIOLOGICAL:** Cetuximab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06064877
- **Lead sponsor:** AVEO Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-11
- **Primary completion:** 2027-08
- **Final completion:** 2027-11
- **Target enrollment:** 410 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06064877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06064877, "A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06064877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*